Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/17/2005WO2005007652A3 Substituted quinolin-4-ylamine analogues
03/17/2005WO2005004919A3 Extended release systems for macrolide antibiotics
03/17/2005WO2005004915A3 Compositions comprising meloxicam
03/17/2005WO2005004808A3 TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
03/17/2005WO2005003087A3 Oxazole derivatives as antibacterial agents
03/17/2005WO2005002570A8 Use of an aziridino compound to selectively inactivate parasites in biological compositions
03/17/2005WO2005002563A3 Method for treating alcoholic hepatitis
03/17/2005WO2005000214A3 Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
03/17/2005WO2004110441A8 Pharmaceutical formulations comprising amoxicillin and clavulanate
03/17/2005WO2004108084A3 Polymorphic forms of naltrexone
03/17/2005WO2004105703A3 Compounds, formulations, and methods for treating or preventing rosacea
03/17/2005WO2004105692A3 Smooth muscle spasmolytic agents
03/17/2005WO2004103376A3 Skin treatments
03/17/2005WO2004103364A3 Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
03/17/2005WO2004103305A3 Spiropyrazole compound
03/17/2005WO2004100875A3 Benzimidazoles, compositions containing such compounds and methods of use
03/17/2005WO2004098501A3 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
03/17/2005WO2004092196A3 Tie-2 modulators and methods of use
03/17/2005WO2004089376A3 Identification and targeting of consensus sites by which dynorphin exerts its neurotoxic effects enables analgesia without neurotoxicity
03/17/2005WO2004087153A3 Use of organic compounds for immunopotentiation
03/17/2005WO2004087061A3 Tubulin binding agents and corresponding prodrug constructs
03/17/2005WO2004084874A3 Mtp inhibitors for inhibiting inflammation
03/17/2005WO2004083383A3 Globin variant gene methods and compositions
03/17/2005WO2004082669A3 Antiflatulents in combibation with histamine h1-receptor antagonist for treating gastrointestinal disoders
03/17/2005WO2004074270B1 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
03/17/2005WO2004072033A3 Pyrazoles and methods of making and using the same
03/17/2005WO2004071399A3 Modulation of atp production or content in the hypothalamus
03/17/2005WO2004069223A3 Pharmaceutical compositions comprising immunosuppressants and uses thereof
03/17/2005WO2004069188A3 Methods for treatment of ibs and nud
03/17/2005WO2004066954A3 A therapeutic composition for the treatment of hiv-1 and hiv-2
03/17/2005WO2004060279A3 Use of silver sulfadiazine for viral aliments, and preparations and combinations therefor
03/17/2005WO2004060146A3 Method of treatment for central nervous system injury
03/17/2005WO2004054601A3 Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
03/17/2005WO2004045612A8 Use of a proton pump inhibitor for preventing postoperative nausea and vomiting
03/17/2005WO2004043408A3 Gpc15: methods and compositions for treating cancer
03/17/2005WO2004041154A3 Abuse-resistant opioid dosage form
03/17/2005WO2004032843A3 Mucoadhesive tetracycline formulations
03/17/2005WO2004004697A8 A novel use of rapamycin and structural analogues thereof
03/17/2005WO2003101425A3 Therapeutic agent-containing polymeric nanoarticles
03/17/2005WO2003092614A3 Lipid removal from the body
03/17/2005WO2003045918A8 Piperidine-based mch antagonists for treatment of obesity and cns disorders
03/17/2005WO2003043619A8 New use for the treatment of gastroesophageal reflux disease
03/17/2005WO2003039578A8 Treatment of congestive heart failure
03/17/2005WO2003037887A8 Therapeutic isoquinoline compounds
03/17/2005WO2003011898A3 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
03/17/2005WO2002079193A8 Inhibitors of cyclin dependent kinases as anti-cancer agent
03/17/2005WO2002050028A8 Substituted benzoindoles as spla2 inhibitors
03/17/2005US20050060770 Antifungal proteins
03/17/2005US20050059828 Process for the preparation of eletriptan
03/17/2005US20050059826 Agonists, antagonists or inverse agonists for brain receptors; anxiolytics, antidepressants; nervous system, sleep and psychological disorders; Down syndrome, cognition activators
03/17/2005US20050059815 Processes for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
03/17/2005US20050059745 Treating drug resistance viral infections such as HIV using a sulfide, sulfone, sulfonyl or sulfonate-functional benzene compound of given formula that inactivate transcription factors such as nuclear factor kappa beta (NF-kb)
03/17/2005US20050059744 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
03/17/2005US20050059743 Methods for treating mild cognitive impairment and alzheimer's disease
03/17/2005US20050059742 Such as 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, or a prostaglandin derivative, or 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809)
03/17/2005US20050059741 Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1
03/17/2005US20050059740 Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
03/17/2005US20050059738 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
03/17/2005US20050059737 Such as 3-pentenoic acid or fatty acid glycerides, using as catalyst a group 8 metal compound with a bis-phosphite ligand to form cyanoalkylcarboxylic acids or glycerides thereof; preparing their corresponding amines
03/17/2005US20050059736 Amidoacetonitrile derivatives
03/17/2005US20050059735 Cyclic amino acid derivatives useful as pharmaceutical agents
03/17/2005US20050059734 Compositions comprising inhibitors of IMPDH enzyme
03/17/2005US20050059733 and stilbene oxides; 3,5-dihydroxy-4-isopropylstilbene for example; treating various immune, inflammatory, and autoimmune diseases
03/17/2005US20050059732 Synthesis of 8-membered carbocyclic compound having diexomethylene groups
03/17/2005US20050059731 Erythrosin-based antimicrobial photodynamic therapy compound and its use
03/17/2005US20050059729 Substituted cyclic compounds
03/17/2005US20050059727 Withanamide and withanolide compositions and method of use thereof
03/17/2005US20050059726 For treating thrombosis and factor xa-related cardiovascular and neurodegenerative diseases; 6-Chloro-N-{(3S)-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide for example
03/17/2005US20050059725 Treating schizophrenia or Parkinson's disease with thiolutin dioxide
03/17/2005US20050059722 Kinase inhibitors, such as focal adhesion kinase (FAK) inhibitors; treating cancer; 2-methylsulfonyl-N-(3-thiophen-2-yl-1H-indazol-5-yl)benzenesulfonamide for example
03/17/2005US20050059721 Nonsedating alpha-2 agonists
03/17/2005US20050059720 Medicinal compositions for the prevention or treatment of cardiac failure
03/17/2005US20050059719 Solid dosage formulation containing a Factor Xa inhibitor and method
03/17/2005US20050059718 Improve the safety anti-epilepsy therapy, reducing the side effect of drug, by informing and monitoring the patient by laboratory test, medical evaluation; adjusting the dosages
03/17/2005US20050059715 Treatment of pain, particularly neuropathic pain; with serotonin re-uptake inhibitor (gabapentin), serotonin re-uptake inhibitor (sertraline, fluoxetine), noradrenaline re-uptake inhibitor (reboxetine) or serotonin-noradrenaline re-uptake inhibitor (venlafaxine)
03/17/2005US20050059714 2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol; treating diseases of inflammatory, allergic, or proliferative condition; type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumor
03/17/2005US20050059712 Immunosuppressants for treating skin disorders, acne, alopecia, estrogen- or androgen-dependent tumors, rheumatoid arthritis, type I and II diabetes, lupus erythematosus, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis, contact dermatitis, graft versus host disease, eczema, asthma
03/17/2005US20050059711 Potentiators of insulin secretion
03/17/2005US20050059709 Multiple sclerosis therapy by administering 5 and less than 18 mg of 4-aminopyridine per dose in at least two doses per day; inhibit central nervous system side effects
03/17/2005US20050059707 Benzoyl-, indanoyl- or tetrahydronaphthoyl-oxy (or thio) nicotinic acid derivatives; a kit comprising two chambers for mixing the compound in solid form with a topical carrier within seven days prior to topical administration
03/17/2005US20050059706 Treatment of diabetes with thiazolidinedione and metformin
03/17/2005US20050059704 5-HT3 agonist is selecting from (R) N-1-azabicyclo[2.2.2]oct-3-yl-4,7-dihydro-7-oxothieno[3,2-b]pyridine-6-carboxamide or 2-(1H-imidazol-4-ylmethyl)-8H-indeno[1,2-d]thiazole; proton pump inhibitor, an H2 receptor antagonist; increasing esophageal motility
03/17/2005US20050059703 Diaryl ureas for diseases mediated by PDGFR
03/17/2005US20050059702 Elevate the progenitor and/or stem cell population in peripheral blood or bone marrow; treatment of HIV, inflammatory condition like rheumatoid arthritis, tumor, asthma; 4-(3,3''-Dimethyl-3',4',5',6'-tetrahydro-2'H-cis-[2,2';6',2'']terpyridin-1'-yl-butylamine
03/17/2005US20050059701 Oral dosage form contains povidone or copovidone binder; HCl-free or non-hygroscopic filler; serotonin reuptake inhibition; stable without lose its hardness after storage
03/17/2005US20050059700 Reacting compunds such as 6-methyl-12-oxa-tricyclo[8.2.1.0]trideca-2,4,6-trien-11-ol with compounds such as 4-(2,6-dichloro-phenyl)-piperidine to produce (+-)-cis-1-methyl-7-[[4-(2,6-dichloro-phenyl)piperidin-1-yl)]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol
03/17/2005US20050059699 N-acylated lipophilic amino acid derivatives
03/17/2005US20050059698 Cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration disease, behavioral or psychological disorders; N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-2,3-dihydro-1,4-benzodioxine-6-carboxamide L-malate; including antipsychotic drugs
03/17/2005US20050059697 Combination of organic compounds
03/17/2005US20050059696 Process for the recovery of S -(+)-methyl- (2-chlorophenyl)- (6,7-dihydro- 4H-thieno [3,2-c] pyrid-5-yl) acetate hydrogen sulfate (clopidogrel bisulfate) from its (R) and mixture of (R) and (S)- isomers
03/17/2005US20050059694 Antiinflammatory and antiproliferative skin agents for Topical administration of treating skin psoriasis disease; lotions, gels, cream
03/17/2005US20050059693 Heterocyclic thioester and ketone hair growth compositions and uses
03/17/2005US20050059691 Novel polymorphic form of 17-beta-(N-ter. butyl carbamoyl)-4-aza-5-alpha-androst-1-en-3-one and a process for preparing it
03/17/2005US20050059690 Method of treating acute pain with a unitary dosage form comprising ibuprofen and oxycodone
03/17/2005US20050059689 Therapy for stroke, cancer, multiple sclerosis, brain disorders, Parkinson's disease, Huntington's diseasee
03/17/2005US20050059688 administering nontoxic, preferential and potent c-kit ligand inhibitors such as imatinib, to humans for treatment of inflammatory diseases such as rheumatoid arthritis
03/17/2005US20050059686 Pyrrolopyrimidines as phosphodiesterase vII inhibitors
03/17/2005US20050059683 A1 adenosine receptor antagonists
03/17/2005US20050059682 Compositions and methods for treatment of cancer
03/17/2005US20050059680 Crystalline ziprasidone HCI and processes for preparation thereof
1 ... 4750 4751 4752 4753 4754 4755 4756 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 4770 ... 7860